scispace - formally typeset
C

Chandani Limbad

Researcher at Buck Institute for Research on Aging

Publications -  16
Citations -  1860

Chandani Limbad is an academic researcher from Buck Institute for Research on Aging. The author has contributed to research in topics: Senescence & Cell growth. The author has an hindex of 9, co-authored 13 publications receiving 1291 citations. Previous affiliations of Chandani Limbad include New York University & University of California, Berkeley.

Papers
More filters
Journal ArticleDOI

Cellular Senescence Is Induced by the Environmental Neurotoxin Paraquat and Contributes to Neuropathology Linked to Parkinson's Disease

TL;DR: It is demonstrated that senescent cell markers are preferentially present within astrocytes in PD brain tissues and that exposure to certain environmental toxins promotes accumulation of senescent cells in the aging brain, which can contribute to dopaminergic neurodegeneration.
Journal ArticleDOI

Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis

TL;DR: It is shown that CBD inhibits human breast cancer cell proliferation and invasion through differential modulation of the extracellular signal-regulated kinase (ERK) and reactive oxygen species (ROS) pathways, and that both pathways lead to down-regulation of Id-1 expression.
Journal ArticleDOI

Cannabidiol Enhances the Inhibitory Effects of Δ9-Tetrahydrocannabinol on Human Glioblastoma Cell Proliferation and Survival

TL;DR: Cannabidiol, the second most abundant plant-derived cannabinoid, in combination with Δ9-THC is tested and it is suggested that the addition of cannabidiole may improve the overall effectiveness of Δ9 -THC in the treatment of glioblastoma in cancer patients.
Journal ArticleDOI

Id-1 Is a Key Transcriptional Regulator of Glioblastoma Aggressiveness and a Novel Therapeutic Target

TL;DR: It is shown that the transcriptional regulator Id-1 plays a critical role in modulating the invasiveness of glioblastoma cell lines and primary gliablastoma cells, and that drugs targeting Id- 1 represent a novel and promising strategy for improving the therapy and outcome of patients with gliOBlastoma.